Clinical Report: DRY EYE: Bolstering the tear film

Overview

This report discusses the importance of maintaining a robust tear film in patients with dry eye disease (DED) to enhance contact lens wearability. It highlights various interventions, including medications and therapies, aimed at improving tear volume and meibomian gland function.

Background

Dry eye disease is a prevalent condition that significantly impacts contact lens wearers, often leading to discomfort and reduced wear time. Addressing ocular surface issues is crucial for maintaining patient satisfaction and enabling long-term contact lens use. Effective management of DED can also facilitate future refractive surgery options for patients.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Dry eye disease affects contact lens tolerability, necessitating interventions to improve tear film stability.
• Medications such as varenicline nasal spray and cyclosporine solutions can increase tear volume.
• Meibomian gland dysfunction (MGD) is common in 30% to 60% of contact lens wearers and contributes to discomfort.
• At-home therapies include warm compresses and eyelid hygiene, while in-office treatments involve thermal pulsation and intense pulsed light.
• Reducing toxic load from contact lens solutions can alleviate symptoms of DED.

Clinical Implications

Clinicians should prioritize the assessment and management of dry eye disease in contact lens wearers to enhance comfort and wear time. A combination of pharmacological and non-pharmacological strategies can be employed to optimize tear film health and address meibomian gland dysfunction effectively.

Conclusion

Maintaining a healthy tear film is essential for the comfort and longevity of contact lens wear. Implementing targeted interventions can significantly improve patient outcomes in those suffering from dry eye disease.

References

1. Stern ME, et al., Exp Eye Res, 2004 -- The role of the lacrimal functional unit in the pathophysiology of dry eye.
2. Mah F, World Cornea Congress VIII, 2022 -- Oral presentation on dry eye treatments.
3. Schaumberg DA, et al., Invest Ophthalmol Vis Sci, 2011 -- Report on the epidemiology of meibomian gland dysfunction.
4. Arita R, Fukuoka S, Clin Exp Optom, 2020 -- Non-pharmaceutical treatment options for meibomian gland dysfunction.
5. Ophthalmology Management — Marketplace
6. Ophthalmology Management — The New Science Behind Artificial Tears
7. Corneal Physician — Dry Eye Disease Treatments: Pharmaceutical vs Procedural
8. contact lens spectrum — Dry Eye Dx and Tx: Malfunctioning Mucins
9. Marketplace Focus on Dry Eye Medications
10. The New Science Behind Artificial Tears
11. Dry Eye Disease Treatments: Pharmaceutical vs Procedural
12. TFOS DEWS III: Diagnostic Methodology
13. Efficacy and safety of perfluorohexyloctane (PFHO) in patients with dry eye disease (DED) due to meibomian gland dysfunction (MGD): Systematic review and meta-analysis - PubMed